Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer.

Journal: JAMA oncology
PMID:

Abstract

IMPORTANCE: Only a small fraction of patients with advanced non-small cell lung cancer (NSCLC) respond to immune checkpoint inhibitor (ICI) treatment. For optimal personalized NSCLC care, it is imperative to identify patients who are most likely to benefit from immunotherapy.

Authors

  • Mehrdad Rakaee
    Department of Medical Biology, UiT The Arctic University of Norway, Tromsø, Norway.
  • Masoud Tafavvoghi
    Faculty of Science and Technology, Department of Computer Science, UiT-The Arctic University of Norway, Tromsø, Norway.
  • Biagio Ricciuti
    Dana-Farber Cancer Institute, Boston, MA, USA.
  • Joao V Alessi
    Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Alessio Cortellini
    Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, Rome, Italy.
  • Fabrizio Citarella
    Medical Oncology Operative Research Unit, Fondazione Policlinico Campus Bio-Medico, Rome, Italy.
  • Lorenzo Nibid
    Research Unit of Anatomical Pathology, Department of Medicine and Surgery, Università Campus Bio-Medico, Rome, Italy.
  • Giuseppe Perrone
    Department of Medicine and Surgery, Research Unit of Anatomical Pathology, Università Campus Bio-Medico di Roma, Roma, Italy.
  • Elio Adib
    Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Claudia A M Fulgenzi
    Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
  • Cassio Murilo Hidalgo Filho
    Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Alessandro Di Federico
    Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Falah Jabar
    Department of Clinical Pathology, University Hospital of North Norway, Tromsø, Norway.
  • Sayed Hashemi
    Department of Pulmonary Medicine, Cancer Center Amsterdam, VU Medical Center, Amsterdam University Medical Center, Amsterdam, the Netherlands.
  • Ilias Houda
    Department of Pulmonary Medicine, Cancer Center Amsterdam, VU Medical Center, Amsterdam University Medical Center, Amsterdam, the Netherlands.
  • Elin Richardsen
    Department of Clinical Pathology, University Hospital of North Norway, Tromsø, Norway.
  • Lill-Tove Rasmussen Busund
    Department of Clinical Pathology, University Hospital of North Norway, Tromsø, Norway.
  • Tom Donnem
    Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway.
  • Idris Bahce
    Department of Pulmonary Medicine, Cancer Center Amsterdam, VU Medical Center, Amsterdam University Medical Center, Amsterdam, the Netherlands.
  • David J Pinato
    Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
  • Åslaug Helland
    Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Lynette M Sholl
    Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Mark M Awad
    Dana-Farber Cancer Institute, Boston, MA, USA.
  • David J Kwiatkowski
    Department of Anatomic Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.